Enclomiphene explained - how it works

A SERM - selective estrogen receptor modulator - is a drug that binds estrogen receptors but acts differently depending on the tissue: in some places it mimics estrogen, in others it blocks it. Enclomiphene is the kind that blocks. Its job in a man's hormone axis is to sit on the estrogen receptors in one specific place, the hypothalamus, and get in estrogen's way there [1].

Testosterone is controlled by a feedback loop. The hypothalamus releases GnRH, which tells the pituitary to release LH and FSH, which tell the testicles to make testosterone. Some of that testosterone is converted to estrogen, and estrogen loops back to the hypothalamus as a "stop" signal - the negative feedback that keeps the loop from running away.

Enclomiphene blocks that stop signal. By occupying the hypothalamic estrogen receptors, it keeps estrogen's feedback from registering, so the hypothalamus behaves as if estrogen is low and keeps the loop running: more GnRH, then more LH and FSH, then more testosterone made by the testicles themselves [1]. In pooled randomized-trial data, SERMs raised LH by a mean 4.66 IU/L and FSH by 4.59 IU/L versus placebo, alongside a 273.76 ng/dL rise in total testosterone [2].

The key contrast with testosterone gel or injections: those add testosterone from outside, which the brain reads as plenty and responds to by shutting LH and FSH down. Enclomiphene does the opposite - it turns the body's own signal up and leaves the testicular machinery working. That is why the fertility-preservation story exists, covered on its own page.

Clomiphene, the parent drug, is not a single molecule. It is a mix of two mirror-image isomers - enclomiphene (the trans form) and zuclomiphene (the cis form). Enclomiphene is the trans isomer isolated out on its own [1].

The two halves behave differently. Enclomiphene, the trans isomer, carries most of the testosterone-raising action and is short-lived: rapidly absorbed with a half-life of roughly 10 hours [1]. Zuclomiphene, the cis isomer, is the estrogenic, slow one - it lingers in the blood for weeks. Purifying clomiphene down to just enclomiphene is meant to keep the testosterone benefit while dropping the long-lasting estrogenic part.

One point worth correcting: enclomiphene is the short-lived isomer, not a long-acting one. The sometimes-repeated claim that enclomiphene itself has a notably long half-life inverts the story - it is zuclomiphene, the isomer left behind, that is the long-lived one.

There is no FDA-approved enclomiphene product. Repros Therapeutics developed it as Androxal and took it through Phase 3 trials in men with secondary (hypogonadotropic) hypogonadism, testing 12.5 mg and 25 mg once-daily oral capsules against placebo [1][3][4]. It had been under FDA review since 2007, but a November 2015 meeting scheduled to review the new drug application was canceled over concerns about the bioanalytical method, and no monotherapy product was ever approved [1].

So every enclomiphene product in use today is compounded - mixed by a pharmacy - and used off-label. That is a materially different status from an FDA-approved drug: no approved label, no standardized product, and long-term safety not established [1]. We are logging what the evidence and the regulatory record say, not endorsing use.

In the Repros Phase 3 program, the two co-primary outcomes were the proportion of men who normalized morning testosterone and the sperm response, run in overweight men with acquired hypogonadotropic hypogonadism [3][4]. Reported side effects in the enclomiphene work included elevated estradiol, headache, and abdominal discomfort, and long-term effects are not established [1].

One class-level caution carries over from clomiphene: the clomiphene-family label warns that visual symptoms - blurring, spots, or flashes (scintillating scotomata) - may occur, usually reversible but rarely prolonged or permanent, and more likely with higher dose or longer use. The label says to stop and get a prompt eye exam if visual symptoms appear [5]. That is a description of the parent-compound label, not medical advice.

For the compound reference and the fertility contrast in full, see the enclomiphene library page and enclomiphene for fertility.